Physician profile
Roy Timothy Webb
NPI 1346227048
$13,803.16
in general payments reported to CMS, 2019-2025
81 companies · $2,754 in 2025
The $2,754 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,752 · 2020: $908 · 2021: $1,437 · 2022: $1,880 · 2023: $2,447 · 2024: $2,626 · 2025: $2,754.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,810 · Education: $15.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,810.31 |
| Education | $15.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,118.10 | 2019-2025 | |
| Pfizer INC. | $907.95 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $836.10 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Astrazeneca Pharmaceuticals Lp | $785.26 | 2019-2025 | Imfinzi, Enhertu |
| Glaxosmithkline, LLC. | $631.29 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Celgene Corporation | $593.60 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Abbvie INC. | $563.55 | 2019-2025 | Venclexta, Lupron Depot |
| Incyte Corporation | $462.62 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Daiichi Sankyo INC. | $445.50 | 2019-2025 | Enhertu, Datroway |
| Genzyme Corporation | $395.82 | 2019-2025 | |
| Astellas Pharma US INC | $386.37 | 2019-2025 | Padcev, Xospata, Vyloy |
| Exelixis INC. | $365.97 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $343.69 | 2019-2025 | Darzalex, Tecvayli, Talvey |
| E.R. Squibb & Sons, L.L.C. | $318.43 | 2019-2025 | Reblozyl, Opdivo, Opdualag |
| Eisai INC. | $302.85 | 2019-2025 |
Show all 77 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $283.61 | 2019-2022 | |
| Gilead Sciences, INC. | $281.27 | 2019-2025 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $268.40 | 2022-2024 | Ninlaro, Fruzaqla, Advate |
| Lilly USA, LLC | $254.58 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Emd Serono, INC. | $251.13 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $236.58 | 2019-2025 | |
| Amgen INC. | $231.78 | 2019-2023 | Lumakras, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $213.83 | 2019-2025 | Libtayo |
| Karyopharm Therapeutics INC. | $204.82 | 2020-2025 | Xpovio |
| Array Biopharma INC | $195.27 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Pharmacyclics LLC, An Abbvie Company | $190.86 | 2019-2023 | Imbruvica |
| Puma Biotechnology, INC. | $166.40 | 2019-2025 | |
| Beigene USA, INC. | $165.01 | 2020-2025 | Brukinsa |
| Sumitomo Pharma America, INC. | $137.11 | 2023-2024 | Orgovyx |
| Ipsen Biopharmaceuticals, INC | $126.52 | 2019-2025 | Onivyde, Tazverik, Somatuline Depot |
| Seagen INC. | $125.00 | 2019-2023 | Tukysa, Adcetris |
| Pharmacosmos Therapeutics INC. | $99.16 | 2023-2025 | Monoferric, Cosela |
| Sobi, INC | $95.09 | 2022-2025 | |
| Rigel Pharmaceuticals, INC. | $93.76 | 2021-2024 | Rezlidhia, Tavalisse |
| Adc Therapeutics America, INC. | $93.54 | 2022-2024 | |
| Amag Pharmaceuticals, INC. | $88.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.10 | 2021-2025 | Gilotrif |
| Mirati Therapeutics, INC. | $86.09 | 2023-2024 | Krazati |
| Kite Pharma, INC. | $77.74 | 2020-2021 | |
| Beone Medicines USA, INC. | $76.65 | 2025 | Brukinsa |
| Myovant Sciences INC. | $72.81 | 2021-2022 | |
| Morphosys, US INC. | $72.15 | 2021-2023 | Monjuvi |
| Spectrum Pharmaceuticals INC. | $72.14 | 2023-2025 | Rolvedon |
| Deciphera Pharmaceuticals INC. | $69.93 | 2021-2025 | Qinlock, Romvimza |
| Heron Therapeutics, INC. | $65.91 | 2021-2023 | Sustol |
| Tesaro, INC. | $60.88 | 2019 | |
| Epizyme, INC. | $58.18 | 2021-2022 | |
| G1 Therapeutics, INC. | $51.31 | 2022-2023 | Cosela |
| Aveo Pharmaceuticals, INC. | $50.07 | 2022-2025 | Fotivda |
| Clovis Oncology, INC. | $47.06 | 2019-2020 | |
| Agios Pharmaceuticals, INC. | $39.67 | 2021-2024 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $38.41 | 2022-2024 | Clonoseq |
| Celltrion USA INC. | $33.72 | 2024-2025 | Vegzelma |
| Geron Corporation | $30.60 | 2024-2025 | Rytelo |
| Janssen Pharmaceuticals, INC | $29.85 | 2020-2022 | |
| Genmab U.S., INC. | $26.74 | 2023-2025 | Epkinly |
| Foundation Medicine, INC. | $25.84 | 2019 | |
| Ucb, INC. | $25.73 | 2025 | Rystiggo |
| Iovance Biotherapeutics, INC. | $25.36 | 2025 | Amtagvi |
| Myriad Genetic Laboratories, INC. | $24.18 | 2025 | Myrisk |
| Springworks Therapeutics, INC. | $23.95 | 2025 | |
| Tersera Therapeutics LLC | $22.89 | 2023 | Xermelo |
| Helsinn Therapeutics (U.S.), INC. | $22.50 | 2019 | |
| Alexion Pharmaceuticals, INC. | $22.20 | 2022 | |
| Dendreon Pharmaceuticals LLC | $20.95 | 2025 | Provenge |
| Apellis Pharmaceuticals, INC. | $20.46 | 2023 | Empaveli |
| Jazz Pharmaceuticals INC. | $18.43 | 2025 | |
| Pharmaessentia USA Corporation | $16.64 | 2023 | Besremi |
| Stemline Therapeutics INC. | $16.39 | 2023 | Orserdu |
| Legend Biotech USA INC. | $15.99 | 2025 | Carvykti |
| Caris Mpi, INC. | $15.81 | 2025 | Mi Cancer Seek |
| Teva Pharmaceuticals USA, INC. | $15.21 | 2019 | |
| Horizon Therapeutics Plc | $14.92 | 2019 | |
| Shield Therapeutics INC | $12.90 | 2023 | Accrufer |
| Sun Pharmaceutical Industries INC. | $12.74 | 2023 | Yonsa, Odomzo |
| Dova Pharmaceuticals | $12.71 | 2020 | |
| Blue Earth Diagnostics | $11.85 | 2021 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.